Akers Biosciences Inc  

(Public, LON:AKR)   Watch this stock  
Find more results for John Rauch
-2.50 (-0.80%)
Apr 27 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 307.00 - 325.00
52 week 195.00 - 325.00
Open 312.50
Vol / Avg. 2,477.00/5,019.00
Mkt cap 16.05M*
P/E     -
Div/yield     -
EPS -0.44*
Shares 5.14M
Beta     -
Inst. own 23%
Mar 23, 2015
Full Year 2014 Akers Biosciences Inc Earnings Call
Mar 23, 2015
Full Year 2014 Akers Biosciences Inc Earnings Release

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -63.05% -70.64%
Operating margin -64.45% -72.37%
EBITD margin - -64.48%
Return on average assets -21.89% -27.52%
Return on average equity -23.97% -33.21%
Employees 24 -
CDP Score - -


201 Grove Rd
WEST DEPTFORD, NJ 08086-2231
United States - Map
+1-856-8488698 (Phone)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance


Akers Biosciences, Inc. (ABI) is a United States-based company. The Company is a designer and manufacturer of rapid diagnostic screening and testing products. The Company�s products include BreathScan, BreathScan PRO, CHUBE, METRON, PIFA Heparin/PF4, PIFA PLUSS PF4, Tri-Cholesterol and VIVO. The Company�s objective is to apply the flexible platforms to the development of rapid tests which fulfill unmet needs in a variety of fields, including cardiology/emergency medicine, infectious disease, metabolism/nutrition, neuropsychiatry and oncology, as well as on and off the job alcohol safety.

Officers and directors

Raymond F. Akers Executive Chairman of the Board, Secretary
Age: 56
John C. Cheneval Executive Vice President, Sales and Marketing
Gary M. Rauch Senior Vice President - Finance, Treasurer
Age: 59
Christopher Ellis Vice President - Global Marketing
Brandon Thomas Knox Independent Director
Age: 35
Thomas James Knox Independent Director
Age: 73
Gavin Edwin David Moran Independent Director
Age: 43